KDA Group Inc.

Equities

KDA

CA48669F1071

Biotechnology & Medical Research

Market Closed - Toronto S.E. 15:47:51 2024-05-13 EDT 5-day change 1st Jan Change
0.395 CAD +3.95% Intraday chart for KDA Group Inc. -7.06% +97.50%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
KDA Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024 CI
KDA Group Inc. Announces an Update in the Development and Use of Its Adherize+ Platform CI
KDA Group Inc. Announces the Appointments of Yves Marmet as General Manager and Chief Technology Officer and Marie-Hélène Pinard as Chief Operating Officer of Groupe Technologique KDA Inc CI
KDA Group Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023 CI
ZoomMed Announced Distribution to Its Shareholders of 5 Million Common Shares It Holds in KDA Group MT
KDA Group Inc. announced that it has received CAD 1.125 million in funding CI
KDA Group Inc. Reports Earnings Results for the Full Year Ended July 31, 2023 CI
KDA Group Inc. Announces Executive Changes CI
KDA Group Inc. acquired Substantially all the assets in the ZRx Prescriber from ZoomMed Medical Inc. for CAD 0.8 million. CI
KDA Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023 CI
KDA Group Inc. Announces Directors Resignation CI
9486-4410 Quebec Inc completed the acquisition of Agence L.I.V. Inc. from KDA Group Inc.. CI
ZoomMed Board Ratifies Asset Sale to KDA Group MT
KDA Group Inc. entered into an agreement to acquire right, title and interest in the ZRx Prescriber from ZoomMed Medical Inc. for CAD 0.8 million. CI
9486-4410 Quebec Inc entered into a share purchase agreement to acquire Agence L.I.V. Inc. from KDA Group Inc. for $13.5 million. CI
Halsa Health Group Inc. entered into a share purchase agreement to acquire Élitis Pharma Inc. and Logistique Pharma Inc. from KDA Group Inc. for $2.1 million. CI
KDA Group Inc. acquired Covapharm Inc for CAD 0.38 million. CI
KDA Group Inc. Reports Earnings Results for the First Quarter Ended October 31, 2022 CI
KDA Group Inc. Reports Earnings Results for the Full Year Ended July 31, 2022 CI
KDA Group Inc. Auditor Raises 'Going Concern' Doubt CI
KDA Group Inc. Appoints Luc Olivier as Chief Financial Officer CI
KDA Group Inc. Announces Executive Changes CI
KDA Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2022 CI
KDA Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2022 CI
KDA Group Inc. and Its Wholly Owned Subsidiary, Groupe Technologique KDA Inc. Announce Partnership with Progitek Dev Inc CI
Chart KDA Group Inc.
More charts
KDA Group Inc. is a Canada-based solution and services provider to pharmacies and pharmaceutical companies in Canada as well as technological platform for the health industry. The Company’s segments include Pharmacy Services, Pharmaceutical Solutions and Pharmaceutical Technology. Its Pharmacy Services segment offers training, consulting, and replacement services for professional resources in the field of healthcare. Its Pharmaceutical Solutions segment is engaged in the development and integration of technological platforms dedicated to all healthcare professionals. Its Pharmaceutical technology segment offers KRX, KRX DENTAL and ADRX platforms. It also offers ZRx Digital Prescriber an electronic prescriber computer and mobile software designed and developed for use by healthcare providers who are authorized to prescribe medications and other treatments. Its subsidiaries include Alliance Pharma Operations Inc., Elitis Pharma Inc., Logistik Pharma Inc. and Groupe Technologique KDA Inc.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. KDA Stock
  4. News KDA Group Inc.
  5. ZoomMed Board Ratifies Asset Sale to KDA Group
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW